HEADER HYDROLASE 19-DEC-11 4ACU TITLE AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA TITLE 2 SECRETASE COMPLEXED WITH COMPOUND 14 COMPND MOL_ID: 1; COMPND 2 MOLECULE: BETA-SECRETASE 1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 43-453; COMPND 5 SYNONYM: ASPARTYL PROTEASE 2, ASP2, ASP 2, BETA-SITE AMYLOID COMPND 6 PRECURSOR PROTEIN CLEAVING ENZYME 1, BETA-SITE APP CLEAVING ENZYME 1, COMPND 7 MEMAPSIN-2, MEMBRANE-ASSOCIATED ASPARTIC PROTEASE 2, BACE-1; COMPND 8 EC: 3.4.23.46; COMPND 9 ENGINEERED: YES; COMPND 10 MUTATION: YES; COMPND 11 OTHER_DETAILS: PROPEPTIDE NUMBERED 484-502 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PET11A KEYWDS HYDROLASE, ALZHEIMER'S DISEASE EXPDTA X-RAY DIFFRACTION AUTHOR B.SWAHN,J.HOLENZ,J.KIHLSTROM,K.KOLMODIN,J.LINDSTROM,N.PLOBECK, AUTHOR 2 D.ROTTICCI,F.SEHGELMEBLE,M.SUNDSTROM,S.VON BERG,J.FALTING, AUTHOR 3 B.GEORGIEVSKA,S.GUSTAVSSON,J.NEELISSEN,M.EK,L.L.OLSSON,S.BERG REVDAT 4 09-OCT-24 4ACU 1 REMARK REVDAT 3 01-MAY-24 4ACU 1 REMARK REVDAT 2 14-FEB-18 4ACU 1 AUTHOR JRNL REVDAT 1 29-FEB-12 4ACU 0 JRNL AUTH B.M.SWAHN,J.HOLENZ,J.KIHLSTROM,K.KOLMODIN,J.LINDSTROM, JRNL AUTH 2 N.PLOBECK,D.ROTTICCI,F.SEHGELMEBLE,M.SUNDSTROM,S.V.BERG, JRNL AUTH 3 J.FALTING,B.GEORGIEVSKA,S.GUSTAVSSON,J.NEELISSEN,M.EK, JRNL AUTH 4 L.L.OLSSON,S.BERG JRNL TITL AMINOIMIDAZOLES AS BACE-1 INHIBITORS: THE CHALLENGE TO JRNL TITL 2 ACHIEVE IN VIVO BRAIN EFFICACY. JRNL REF BIOORG. MED. CHEM. LETT. V. 22 1854 2012 JRNL REFN ESSN 1464-3405 JRNL PMID 22325942 JRNL DOI 10.1016/J.BMCL.2012.01.079 REMARK 2 REMARK 2 RESOLUTION. 1.75 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.1 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.75 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 26.34 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 38714 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.176 REMARK 3 R VALUE (WORKING SET) : 0.174 REMARK 3 FREE R VALUE : 0.212 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.010 REMARK 3 FREE R VALUE TEST SET COUNT : 1939 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 19 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.75 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.80 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.06 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2801 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.3645 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2649 REMARK 3 BIN R VALUE (WORKING SET) : 0.3605 REMARK 3 BIN FREE R VALUE : 0.4349 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.43 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 152 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2928 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 45 REMARK 3 SOLVENT ATOMS : 442 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 24.45 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.42 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.39710 REMARK 3 B22 (A**2) : 0.49410 REMARK 3 B33 (A**2) : 2.90290 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.194 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.124 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.116 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.114 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.111 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.957 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.936 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 3097 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 4221 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1040 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 75 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 466 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 3097 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 393 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 3911 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.11 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 4.20 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 15.07 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: IDEAL-DIST CONTACT TERM CONTACT SETUP. REMARK 3 ALL ATOMS HAVE CCP4 ATOM TYPE FROM LIBRARY REMARK 4 REMARK 4 4ACU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-DEC-11. REMARK 100 THE DEPOSITION ID IS D_1290050733. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-DEC-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-E REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 38789 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.750 REMARK 200 RESOLUTION RANGE LOW (A) : 26.300 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.04000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 18.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.80 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.7 REMARK 200 DATA REDUNDANCY IN SHELL : 2.50 REMARK 200 R MERGE FOR SHELL (I) : 0.43000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PREVIOUSLY DETERMINED BACE-1 STRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.05 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 11% PEG6K, 90 MM NAAC PH 5.0, 18 MM REMARK 280 TRIS PH 8.5, 135 MM NACL. REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 23.79400 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.10650 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 38.18600 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.10650 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 23.79400 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 38.18600 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ARG 56 TO LYS REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ARG 57 TO LYS REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LEU A 484 REMARK 465 PRO A 485 REMARK 465 ARG A 486 REMARK 465 GLU A 487 REMARK 465 THR A 488 REMARK 465 ASP A 489 REMARK 465 GLU A 490 REMARK 465 GLU A 491 REMARK 465 PRO A 492 REMARK 465 GLU A 493 REMARK 465 GLU A 494 REMARK 465 PRO A 495 REMARK 465 GLY A 496 REMARK 465 LYS A 497 REMARK 465 LYS A 498 REMARK 465 ALA A 157 REMARK 465 GLY A 158 REMARK 465 PHE A 159 REMARK 465 PRO A 160 REMARK 465 LEU A 161 REMARK 465 ASN A 162 REMARK 465 GLN A 163 REMARK 465 SER A 164 REMARK 465 GLU A 165 REMARK 465 VAL A 166 REMARK 465 LEU A 167 REMARK 465 ALA A 168 REMARK 465 SER A 169 REMARK 465 VAL A 170 REMARK 465 ASP A 378 REMARK 465 MET A 379 REMARK 465 ASN A 385 REMARK 465 ILE A 386 REMARK 465 PRO A 387 REMARK 465 GLN A 388 REMARK 465 THR A 389 REMARK 465 ASP A 390 REMARK 465 GLU A 391 REMARK 465 SER A 392 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 VAL A 69 79.97 -115.05 REMARK 500 PHE A 108 -60.88 -98.71 REMARK 500 TRP A 197 -85.10 -141.20 REMARK 500 ALA A 323 32.34 -95.55 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A 1503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A 1504 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A 1505 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE QN7 A 1506 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1FKN RELATED DB: PDB REMARK 900 STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR REMARK 900 RELATED ID: 1M4H RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITHINHIBITOR OM00-3 REMARK 900 RELATED ID: 1PY1 RELATED DB: PDB REMARK 900 COMPLEX OF GGA1-VHS DOMAIN AND BETA-SECRETASE C- REMARK 900 TERMINALPHOSPHOPEPTIDE REMARK 900 RELATED ID: 1SGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTICDOMAIN. REMARK 900 RELATED ID: 1TQF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH L-124,671 REMARK 900 RELATED ID: 1UJJ RELATED DB: PDB REMARK 900 VHS DOMAIN OF HUMAN GGA1 COMPLEXED WITH C-TERMINAL PEPTIDEFROM BACE REMARK 900 RELATED ID: 1UJK RELATED DB: PDB REMARK 900 VHS DOMAIN OF HUMAN GGA1 COMPLEXED WITH C- TERMINALPHOSPHOPEPTIDE REMARK 900 FROM BACE REMARK 900 RELATED ID: 1W50 RELATED DB: PDB REMARK 900 APO STRUCTURE OF BACE (BETA SECRETASE) REMARK 900 RELATED ID: 1W51 RELATED DB: PDB REMARK 900 BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON -PEPTIDIC REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1XN2 RELATED DB: PDB REMARK 900 NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE. REMARK 900 RELATED ID: 1XN3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONGINHIBITOR WITH REMARK 900 ADDITIONAL UPSTREAM RESIDUES. REMARK 900 RELATED ID: 1XS7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVELINHIBITOR REMARK 900 BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA- SECRETASE). REMARK 900 RELATED ID: 1YM2 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITHNVP-AUR200 REMARK 900 RELATED ID: 1YM4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITHNVP-AMK640 REMARK 900 RELATED ID: 2B8L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH L-000384950 REMARK 900 RELATED ID: 2B8V RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L-L000430, REMARK 900 469 REMARK 900 RELATED ID: 2FDP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- REMARK 900 ETHYLENE INHIBITOR REMARK 900 RELATED ID: 2VA5 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C REMARK 900 RELATED ID: 2VA6 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24 REMARK 900 RELATED ID: 2VA7 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27 REMARK 900 RELATED ID: 2VIE RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-1-BENZYL- 2-HYDROXY-3-((1,1, REMARK 900 5-TRIMETHYLHEXYL)AMINO)PROPYL)-3 -(ETHYLAMINO)-5-(2-OXOPYRROLIDIN-1- REMARK 900 YL)BENZAMIDE REMARK 900 RELATED ID: 2VIJ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 3-(1,1- DIOXIDOTETRAHYDRO-2H-1,2- REMARK 900 THIAZIN-2-YL)-5-(ETHYLAMINO )-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)- REMARK 900 3-(1,2,3 ,4-TETRAHYDRO-1-NAPHTHALENYLAMINO)PROPYL)BENZAMIDE REMARK 900 RELATED ID: 2VIY RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)- 2- REMARK 900 (CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2- HYDROXY-1- REMARK 900 (PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL) BENZAMIDE REMARK 900 RELATED ID: 2VIZ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)- 2- REMARK 900 (CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2- HYDROXY-1- REMARK 900 (PHENYLMETHYL)PROPYL)-3-(2-OXO-1- PYRROLIDINYL)-5-(PROPYLOXY) REMARK 900 BENZAMIDE REMARK 900 RELATED ID: 2VJ6 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)- 2- REMARK 900 (CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2- HYDROXY-1- REMARK 900 (PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2- OXO-1-PYRROLIDINYL) REMARK 900 BENZAMIDE REMARK 900 RELATED ID: 2VJ7 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S, 2R)-2-HYDROXY-1- REMARK 900 (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL) PHENYL)METHYL)AMINO)PROPYL)- REMARK 900 5-(2-OXO-1-PYRROLIDINYL) BENZAMIDE REMARK 900 RELATED ID: 2VJ9 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-( CYCLOHEXYLAMINO)-2- REMARK 900 HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-( ETHYLAMINO)-5-(2-OXO-1- REMARK 900 PYRROLIDINYL)BENZAMIDE REMARK 900 RELATED ID: 2VKM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA- SECRETASE) REMARK 900 RELATED ID: 2VNM RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 3-(1,1- DIOXIDOTETRAHYDRO-2H-1,2- REMARK 900 THIAZIN-2-YL)-5-(ETHYLAMINO )-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)- REMARK 900 3-(((3-( TRIFLUOROMETHYL)PHENYL)METHYL)AMINO)PROPYL)BENZAMIDE REMARK 900 RELATED ID: 2VNN RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)- 2-HYDROXY-1- REMARK 900 (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL) PHENYL)METHYL)AMINO)PROPYL)- REMARK 900 1-METHYL-3,4-DIHYDRO-1H -(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9- REMARK 900 CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 2WEZ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S,2R)- 2-HYDROXY-3-(((3- REMARK 900 (METHYLOXY)PHENYL)METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-4-(2-OXO-1- REMARK 900 PYRROLIDINYL)-1H- INDOLE-6-CARBOXAMIDE REMARK 900 RELATED ID: 2WF0 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)- 2-HYDROXY-1- REMARK 900 (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL) PHENYL)METHYL)AMINO)PROPYL)- REMARK 900 8-(2-OXO-1-PYRROLIDINYL)- 6-QUINOLINECARBOXAMIDE REMARK 900 RELATED ID: 2WF1 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)- 2-HYDROXY-3-(((3- REMARK 900 (METHYLOXY)PHENYL(METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-1-METHYL-3, REMARK 900 4-DIHYDRO-1H-(1,2, 5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2, REMARK 900 2 -DIOXIDE REMARK 900 RELATED ID: 2WF2 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S,2R)- 2-HYDROXY-3-(((3- REMARK 900 (METHYLOXY)PHENYL)METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-1-METHYL-3, REMARK 900 4,7,8-TETRAHYDRO-1H ,6H-(1,2,5)THIADIAZEPINO(5,4,3-DE)QUINOXALINE- REMARK 900 10 -CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 2WF3 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S, 2R)-2-HYDROXY-3- REMARK 900 (((3-(METHYLOXY)PHENYL)METHYL)AMINO)- 1-(PHENYLMETHYL)PROPYL)-1- REMARK 900 METHYL-1,3,4,5-TETRAHYDRO -2,1-BENZOTHIAZEPINE-8-CARBOXAMIDE 2,2- REMARK 900 DIOXIDE REMARK 900 RELATED ID: 2WF4 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N -((1S)-2-OXO-1- REMARK 900 (PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN -4-YLAMINO)PROPYL)-1,3,4,6- REMARK 900 TETRAHYDRO(1,2) THIAZEPINO(5,4,3-CD)INDOLE-8-CARBOXAMIDE 2,2- REMARK 900 DIOXIDE REMARK 900 RELATED ID: 2WJO RELATED DB: PDB REMARK 900 HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC REMARK 900 ACID (2-(2-AM INO-6-PHENOXY-4H- QUINAZOLIN-3-YL)-2 -CYCLOHEXYL- REMARK 900 ETHYL)-AMIDE REMARK 900 RELATED ID: 2XFI RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)- 2- REMARK 900 (CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2- HYDROXY-1- REMARK 900 (PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL )AMINO)BENZAMIDE REMARK 900 RELATED ID: 2XFJ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)- 2- REMARK 900 (CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2- HYDROXY-1- REMARK 900 (PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2- OXO-1-PYRROLIDINYL) REMARK 900 BENZAMIDE REMARK 900 RELATED ID: 2XFK RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)- 2- REMARK 900 (CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2- HYDROXY-1- REMARK 900 (PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(( METHYLSULFONYL)(PHENYL) REMARK 900 AMINO)BENZAMIDE REMARK 900 RELATED ID: 4ACX RELATED DB: PDB REMARK 900 AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF REMARK 900 BETA SECRETASE COMPLEXED WITH COMPOUND 23 DBREF 4ACU A 484 502 UNP P56817 BACE1_HUMAN 43 61 DBREF 4ACU A 1 392 UNP P56817 BACE1_HUMAN 62 453 SEQADV 4ACU LYS A 497 UNP P56817 ARG 56 ENGINEERED MUTATION SEQADV 4ACU LYS A 498 UNP P56817 ARG 57 ENGINEERED MUTATION SEQRES 1 A 411 LEU PRO ARG GLU THR ASP GLU GLU PRO GLU GLU PRO GLY SEQRES 2 A 411 LYS LYS GLY SER PHE VAL GLU MET VAL ASP ASN LEU ARG SEQRES 3 A 411 GLY LYS SER GLY GLN GLY TYR TYR VAL GLU MET THR VAL SEQRES 4 A 411 GLY SER PRO PRO GLN THR LEU ASN ILE LEU VAL ASP THR SEQRES 5 A 411 GLY SER SER ASN PHE ALA VAL GLY ALA ALA PRO HIS PRO SEQRES 6 A 411 PHE LEU HIS ARG TYR TYR GLN ARG GLN LEU SER SER THR SEQRES 7 A 411 TYR ARG ASP LEU ARG LYS GLY VAL TYR VAL PRO TYR THR SEQRES 8 A 411 GLN GLY LYS TRP GLU GLY GLU LEU GLY THR ASP LEU VAL SEQRES 9 A 411 SER ILE PRO HIS GLY PRO ASN VAL THR VAL ARG ALA ASN SEQRES 10 A 411 ILE ALA ALA ILE THR GLU SER ASP LYS PHE PHE ILE ASN SEQRES 11 A 411 GLY SER ASN TRP GLU GLY ILE LEU GLY LEU ALA TYR ALA SEQRES 12 A 411 GLU ILE ALA ARG PRO ASP ASP SER LEU GLU PRO PHE PHE SEQRES 13 A 411 ASP SER LEU VAL LYS GLN THR HIS VAL PRO ASN LEU PHE SEQRES 14 A 411 SER LEU GLN LEU CYS GLY ALA GLY PHE PRO LEU ASN GLN SEQRES 15 A 411 SER GLU VAL LEU ALA SER VAL GLY GLY SER MET ILE ILE SEQRES 16 A 411 GLY GLY ILE ASP HIS SER LEU TYR THR GLY SER LEU TRP SEQRES 17 A 411 TYR THR PRO ILE ARG ARG GLU TRP TYR TYR GLU VAL ILE SEQRES 18 A 411 ILE VAL ARG VAL GLU ILE ASN GLY GLN ASP LEU LYS MET SEQRES 19 A 411 ASP CYS LYS GLU TYR ASN TYR ASP LYS SER ILE VAL ASP SEQRES 20 A 411 SER GLY THR THR ASN LEU ARG LEU PRO LYS LYS VAL PHE SEQRES 21 A 411 GLU ALA ALA VAL LYS SER ILE LYS ALA ALA SER SER THR SEQRES 22 A 411 GLU LYS PHE PRO ASP GLY PHE TRP LEU GLY GLU GLN LEU SEQRES 23 A 411 VAL CYS TRP GLN ALA GLY THR THR PRO TRP ASN ILE PHE SEQRES 24 A 411 PRO VAL ILE SER LEU TYR LEU MET GLY GLU VAL THR ASN SEQRES 25 A 411 GLN SER PHE ARG ILE THR ILE LEU PRO GLN GLN TYR LEU SEQRES 26 A 411 ARG PRO VAL GLU ASP VAL ALA THR SER GLN ASP ASP CYS SEQRES 27 A 411 TYR LYS PHE ALA ILE SER GLN SER SER THR GLY THR VAL SEQRES 28 A 411 MET GLY ALA VAL ILE MET GLU GLY PHE TYR VAL VAL PHE SEQRES 29 A 411 ASP ARG ALA ARG LYS ARG ILE GLY PHE ALA VAL SER ALA SEQRES 30 A 411 CYS HIS VAL HIS ASP GLU PHE ARG THR ALA ALA VAL GLU SEQRES 31 A 411 GLY PRO PHE VAL THR LEU ASP MET GLU ASP CYS GLY TYR SEQRES 32 A 411 ASN ILE PRO GLN THR ASP GLU SER HET ACT A1503 4 HET ACT A1504 4 HET ACT A1505 4 HET QN7 A1506 33 HETNAM ACT ACETATE ION HETNAM QN7 (8S)-3,3-DIFLUORO-8-(2'-FLUORO-3'-METHOXYBIPHENYL-3- HETNAM 2 QN7 YL)-8-PYRIDIN-4-YL-2,3,4,8-TETRAHYDROIMIDAZO[1,5- HETNAM 3 QN7 A]PYRIMIDIN-6-AMINE FORMUL 2 ACT 3(C2 H3 O2 1-) FORMUL 5 QN7 C24 H20 F3 N5 O FORMUL 6 HOH *442(H2 O) HELIX 1 1 SER A 500 VAL A 3 1 6 HELIX 2 2 GLN A 53 SER A 57 5 5 HELIX 3 3 TYR A 123 ALA A 127 5 5 HELIX 4 4 PRO A 135 THR A 144 1 10 HELIX 5 5 ASP A 180 SER A 182 5 3 HELIX 6 6 ASP A 216 TYR A 222 5 7 HELIX 7 7 LYS A 238 SER A 252 1 15 HELIX 8 8 PRO A 258 LEU A 263 1 6 HELIX 9 9 PRO A 276 PHE A 280 5 5 HELIX 10 10 LEU A 301 TYR A 305 1 5 HELIX 11 11 ASP A 311 SER A 315 5 5 HELIX 12 12 GLY A 334 GLU A 339 1 6 SHEET 1 AA 2 LEU A 6 LYS A 9 0 SHEET 2 AA 2 GLY A 13 VAL A 20 -1 O GLY A 13 N LYS A 9 SHEET 1 AB 2 ARG A 61 TYR A 71 0 SHEET 2 AB 2 GLY A 74 SER A 86 -1 O GLY A 74 N TYR A 71 SHEET 1 AC 5 GLY A 172 ILE A 176 0 SHEET 2 AC 5 PHE A 150 LEU A 154 -1 O SER A 151 N ILE A 175 SHEET 3 AC 5 PHE A 341 ASP A 346 -1 O PHE A 341 N LEU A 154 SHEET 4 AC 5 ARG A 351 SER A 357 -1 O ARG A 351 N ASP A 346 SHEET 5 AC 5 TYR A 184 PRO A 192 -1 O THR A 185 N VAL A 356 SHEET 1 AD 5 GLU A 200 VAL A 201 0 SHEET 2 AD 5 SER A 225 VAL A 227 -1 O SER A 225 N VAL A 201 SHEET 3 AD 5 THR A 331 MET A 333 1 O THR A 331 N ILE A 226 SHEET 4 AD 5 LEU A 234 PRO A 237 -1 O ARG A 235 N VAL A 332 SHEET 5 AD 5 ILE A 324 SER A 327 1 O SER A 325 N LEU A 236 SHEET 1 AE 5 GLN A 211 ASP A 212 0 SHEET 2 AE 5 ILE A 203 ILE A 208 -1 O ILE A 208 N GLN A 211 SHEET 3 AE 5 ILE A 283 MET A 288 -1 O SER A 284 N GLU A 207 SHEET 4 AE 5 GLN A 294 ILE A 300 -1 O PHE A 296 N LEU A 287 SHEET 5 AE 5 ALA A 369 VAL A 375 -1 O ALA A 369 N THR A 299 SHEET 1 AF 3 VAL A 268 GLN A 271 0 SHEET 2 AF 3 ASP A 317 PHE A 322 -1 O ASP A 318 N TRP A 270 SHEET 3 AF 3 LEU A 306 PRO A 308 -1 O ARG A 307 N LYS A 321 SSBOND 1 CYS A 155 CYS A 359 1555 1555 2.04 SSBOND 2 CYS A 217 CYS A 382 1555 1555 2.03 SSBOND 3 CYS A 269 CYS A 319 1555 1555 2.03 CISPEP 1 SER A 22 PRO A 23 0 2.12 CISPEP 2 ARG A 128 PRO A 129 0 2.62 CISPEP 3 TYR A 222 ASP A 223 0 0.08 CISPEP 4 GLY A 372 PRO A 373 0 -1.18 SITE 1 AC1 4 GLY A 34 TYR A 198 QN7 A1506 HOH A2058 SITE 1 AC2 7 ALA A 43 PRO A 44 HIS A 45 ILE A 102 SITE 2 AC2 7 THR A 103 SER A 105 PHE A 109 SITE 1 AC3 2 LEU A 188 TRP A 189 SITE 1 AC4 21 SER A 10 GLY A 11 GLN A 12 GLY A 13 SITE 2 AC4 21 LEU A 30 ASP A 32 SER A 35 TYR A 71 SITE 3 AC4 21 GLN A 73 TRP A 76 PHE A 108 ILE A 110 SITE 4 AC4 21 TRP A 115 ILE A 118 ASP A 228 SER A 229 SITE 5 AC4 21 GLY A 230 THR A 231 THR A 232 ACT A1503 SITE 6 AC4 21 HOH A2058 CRYST1 47.588 76.372 104.213 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021014 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013094 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009596 0.00000